Cargando…

Next Steps for Immunotherapy in Glioblastoma

SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Toni Q., Wainwright, Derek A., Lee-Chang, Catalina, Miska, Jason, Sonabend, Adam M., Heimberger, Amy B., Lukas, Rimas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406905/
https://www.ncbi.nlm.nih.gov/pubmed/36011015
http://dx.doi.org/10.3390/cancers14164023
_version_ 1784774235492712448
author Cao, Toni Q.
Wainwright, Derek A.
Lee-Chang, Catalina
Miska, Jason
Sonabend, Adam M.
Heimberger, Amy B.
Lukas, Rimas V.
author_facet Cao, Toni Q.
Wainwright, Derek A.
Lee-Chang, Catalina
Miska, Jason
Sonabend, Adam M.
Heimberger, Amy B.
Lukas, Rimas V.
author_sort Cao, Toni Q.
collection PubMed
description SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies. ABSTRACT: Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy.
format Online
Article
Text
id pubmed-9406905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94069052022-08-26 Next Steps for Immunotherapy in Glioblastoma Cao, Toni Q. Wainwright, Derek A. Lee-Chang, Catalina Miska, Jason Sonabend, Adam M. Heimberger, Amy B. Lukas, Rimas V. Cancers (Basel) Review SIMPLE SUMMARY: Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies. ABSTRACT: Outcomes for glioblastoma (GBM) patients undergoing standard of care treatment remain poor. Here we discuss the portfolio of previously investigated immunotherapies for glioblastoma, including vaccine therapy and checkpoint inhibitors, as well as novel emerging therapeutic approaches. In addition, we explore the factors that potentially influence response to immunotherapy, which should be considered in future research aimed at improving immunotherapy efficacy. MDPI 2022-08-20 /pmc/articles/PMC9406905/ /pubmed/36011015 http://dx.doi.org/10.3390/cancers14164023 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cao, Toni Q.
Wainwright, Derek A.
Lee-Chang, Catalina
Miska, Jason
Sonabend, Adam M.
Heimberger, Amy B.
Lukas, Rimas V.
Next Steps for Immunotherapy in Glioblastoma
title Next Steps for Immunotherapy in Glioblastoma
title_full Next Steps for Immunotherapy in Glioblastoma
title_fullStr Next Steps for Immunotherapy in Glioblastoma
title_full_unstemmed Next Steps for Immunotherapy in Glioblastoma
title_short Next Steps for Immunotherapy in Glioblastoma
title_sort next steps for immunotherapy in glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406905/
https://www.ncbi.nlm.nih.gov/pubmed/36011015
http://dx.doi.org/10.3390/cancers14164023
work_keys_str_mv AT caotoniq nextstepsforimmunotherapyinglioblastoma
AT wainwrightdereka nextstepsforimmunotherapyinglioblastoma
AT leechangcatalina nextstepsforimmunotherapyinglioblastoma
AT miskajason nextstepsforimmunotherapyinglioblastoma
AT sonabendadamm nextstepsforimmunotherapyinglioblastoma
AT heimbergeramyb nextstepsforimmunotherapyinglioblastoma
AT lukasrimasv nextstepsforimmunotherapyinglioblastoma